Organization
University of Sydney and Sydney Cancer Centre
16 abstracts
Abstract
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.Org: Melanoma Institute Australia, Mater and Royal North Shore Hospitals, Leiden University Medical Center, University Medical Center Utrecht, University Medical Center Groningen,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.Org: Netherlands Cancer Institute (NKI-AVL), The Netherlands Cancer Institute, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals,
Abstract
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.Org: University Hospital Zurich, Aix-Marseille University CHU Timone, Hôpital de la Timone, Department of Cancer Medicine, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Campus,
Abstract
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.Org: MD Anderson Cancer Center, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, University of British Columbia, Institut Curie, Saint Cloud, France, University of Bologna,
Abstract
ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.Org: St. John of God Hospital Subiaco, Queen Elizabeth Hospital, University of Adelaide, Woodville, St. George Hospital,
Abstract
Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.Org: Austin Health and Peter MacCallum Cancer Centre, Melbourne, Australia, Garvan Institute of Medical Research, Sydney, Australia, The Kinghorn Cancer Centre,
Abstract
Successful management of Australian patients with locally advanced keratinocyte cancer (KC) and/or extensive skin field cancerization (ESFC), using widefield volumetric arc radiation therapy (VMAT): Report with 24-month follow-up.Org: GenesisCare, Fort Myers, FL, St. Vincent's Hospital, Veracity Clinical Research, University of Sydney and Sydney Cancer Centre, St Vincent's Hospital,
Abstract
GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).Org: Australian & New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Chris O'Brien Lifehouse, Garvan Institute of Medical Research, Centre for Biostatistics and Clinical Trials, Peter Maccallum Cancer Centre, Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Center,
Abstract
Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain.Org: National Cancer Center Japan, University of Notre Dame, Flinders University, Adelaide, SA, Australia, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Japanese Organisation for Research and Treatment of Cancer (JORTC) Data Center,
Abstract
A multicentre randomised controlled trial of zoledronic acid for osteoarthritis of the knee with bone marrow lesionsOrg: Menzies Institute for Medical Research, University of Tasmania, Hobart W. Harris, The Queen Elizabeth Hospital Kings Lynn NHS Trust, Woodville,
Abstract
A SINGLE INFUSION OF ZOLEDRONIC ACID 5 MG IS SIGNIFICANTLY MORE EFFECTIVE THAN DAILY ORAL RISEDRONATE 5 MG IN INCREASING BONE MINERAL DENSITY OF THE LUMBAR SPINE, HIP, FEMORAL NECK AND TROCHANTER IN PATIENTS WITH GLUCOCORTICOID-INDUCED OSTEOPOROSISOrg: University of Aberdeen, Unité de Rhumatolgie, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Paris-Descartes University, Paris, France, University of Dundee,
Abstract
B-LYMPHOCYTE FUNCTION IS ALTERED BY PROTEASE ACTIVATED RECEPTOR-1 Org: Sutton, Laboratory of Tissue Engineering, Institute of Bone and Joint Research, Sydney, Kolling Institute, University of Sydney and Sydney Cancer Centre,
Abstract
Biosimilar medicine is acceptable to patients if recommended by a rheumatologist in an australian tertiary ra cohortOrg: University of Sydney and Sydney Cancer Centre, Monash Health, Bentleigh East, VIC, Australia, Monash University School of Public Health and Preventive Medicine,
Abstract
ASSOCIATIONS BETWEEN METABOLIC STATUS AND ALL-CAUSE MORTALITY AMONG INDIVIDUALS WITH OSTEOARTHRITIS: A PROSPECTIVE COHORT STUDY FROM THE UK BIOBANK AND NHANES DATASETSOrg: Zhujiang Hospital, Southern Medical University, Clinical Research Centre, General Hospital of Southern Theater Command of PLA, Department of Orthopedics, Clinical Research Centre, Guangzhou, China, The Hong Kong Polytechnic University,
Abstract
ASSOCIATION OF HEALTHY LIFESTYLES WITH ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY AMONG INDIVIDUALS WITH OSTEOARTHRITIS: A PROSPECTIVE COHORT STUDY OF THE UK BIOBANKOrg: Zhujiang Hospital, Southern Medical University, Clinical Research Centre, Guangzhou JOYO Pharma, China National Biotec Group,